DBV Technologies (DBVT) to Release Earnings on Friday

DBV Technologies (NASDAQ:DBVT) is expected to release its Q4 2025 results before the market opens on Friday, April 10th. Analysts expect DBV Technologies to post earnings of ($0.1564) per share and revenue of $1.0890 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, April 2, 2026 at 7:00 AM ET.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Saturday, February 14th. The company reported ($1.15) earnings per share for the quarter. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 189.17%. The business had revenue of $0.65 million during the quarter. On average, analysts expect DBV Technologies to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

DBV Technologies Trading Up 0.4%

NASDAQ DBVT opened at $20.45 on Wednesday. DBV Technologies has a 1-year low of $6.69 and a 1-year high of $26.18. The company has a 50 day moving average of $21.29 and a 200-day moving average of $17.87. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -3.92 and a beta of -0.94.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada acquired a new position in shares of DBV Technologies during the fourth quarter worth $34,000. Truvestments Capital LLC increased its holdings in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of DBV Technologies in the fourth quarter worth $115,000. Cetera Investment Advisers bought a new stake in shares of DBV Technologies in the fourth quarter worth $251,000. Finally, Two Sigma Investments LP bought a new stake in shares of DBV Technologies in the third quarter worth $167,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Citizens Jmp lifted their price target on shares of DBV Technologies from $45.00 to $47.00 and gave the company a “market outperform” rating in a research report on Friday, March 27th. Guggenheim reiterated a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research report on Friday, March 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Finally, Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, DBV Technologies presently has an average rating of “Moderate Buy” and an average price target of $38.65.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.